A new medical test developed by Renatek, a Japanese company, is set to launch in December. The test, called the Metal Balance Test, requires only 6 mL of blood to evaluate the risk of cancer and mild cognitive impairment. The test is being introduced at the Shirokawa Hospital in Gifu Prefecture.
The test analyzes metal levels in the blood to identify potential health risks. Early detection of cancer and cognitive decline is a key focus of the initiative. The hospital has begun accepting reservations for the test. Patients will be able to schedule appointments starting in December.
Renatek has been working on this technology for several years. The company has focused on developing non-invasive diagnostic tools that provide early warnings for chronic diseases. This test is part of a broader effort to improve early diagnosis and treatment outcomes. The test is expected to be widely adopted in Japan, with plans for future expansion.
